Plasma concentrations of inteyleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction

被引:86
作者
Geppert, Alexander [1 ]
Dorninger, Angela
Delle-Karth, Georg
Zorn, Gerlinde
Heinz, Gottfried
Huber, Kurt
机构
[1] Univ Vienna, Dept Cardiol, Intens Care Unit, Vienna, Austria
[2] Wilhelminenhosp, Dept Med Cardiol & Emergency Med 3, Intens Care Unit, Vienna, Austria
关键词
interleukin-6; cardiogenic shock; acute myocardial infarction; renal failure; mortality;
D O I
10.1097/01.CCM.0000228919.33620.D9
中图分类号
R4 [临床医学];
学科分类号
1002 [临床医学]; 100602 [中西医结合临床];
摘要
Objective: Inflammation may play an important role in the pathogenesis, persistence, and prognosis of cardiogenic shock. We analyzed whether elevated plasma concentrations of inflammatory markers are independently associated with an adverse prognosis (increased 30-day mortality rate) in patients with cardiogenic shock. Design: Retrospective study. Setting., Single-center study, eight-bed intensive care unit at a university hospital. Patients: Retrospective study on stored plasma samples from 38 patients with cardiogenic shock complicating acute myocardial infarction. Interventions. None. Measurements and Main Results. Thirty-day nonsurvivors (n = 23, 61%) had been less frequently successfully revascularized, exhibited more frequently renal failure, needed higher vasopressor doses, and presented with significantly higher interleukin-6 plasma concentrations on intensive care unit admission than 30-day survivors. Univariate hazard ratios (95% confidence interval) for 30-day mortality were 1.49 (1.24-1.80) for every 50 pg/mL increase in the interleukin-6 plasma concentration (p =.00003), 1.06 (1.02-1.10) for every 0.1 mu g.kg(-1).min(-1) increase in the total vasopressor dose (p =.007), 1.14 (1.04-1.25) for every mmol/L increase in serum lactate (p =.006), 2.47 (1.06-5.73) for acute renal failure (p =.036), and 0.34 (0.14-0.82) for successful revascularization (p =.016). However, interleukin-6 plasma concentrations were correlated with vasopressor need and were significantly higher in patients with acute renal failure and in patients without or unsuccessful revascularization. In a multivarlate Cox-proportional hazard model, interleukin-6 was the only significant predictor of 30-day mortality with a hazard ratio of 1.42 (1.12-1.80, p =.004). Accordingly, interleukin-6 concentrations >= 200 pg/mL (the point of maximum interest by receiver operating characteristic analysis with a specificity of 87% and a sensitivity of 74%) were associated with a significantly increased 30-day mortality rate in both patients with and patients without successful revascularization. Conclusions: Interleukin-6 concentrations are an independent predictor of 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.
引用
收藏
页码:2035 / 2042
页数:8
相关论文
共 35 条
[1]
Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation [J].
Antoniucci, D ;
Valenti, R ;
Migliorini, A ;
Moschi, G ;
Trapani, M ;
Dovellini, EV ;
Bolognese, L ;
Santoro, GM .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (04) :353-357
[3]
Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation [J].
Brunkhorst, FM ;
Clark, AL ;
Forycki, ZF ;
Anker, SD .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 1999, 72 (01) :3-10
[4]
CURRENT CONCEPTS - CARDIOGENIC-SHOCK [J].
CALIFF, RM ;
BENGTSON, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (24) :1724-1730
[5]
ROLE OF CYTOKINES IN THE PATHOGENESIS OF CARDIOPULMONARY-INDUCED MULTISYSTEM ORGAN FAILURE [J].
CASEY, LC .
ANNALS OF THORACIC SURGERY, 1993, 56 (05) :S92-S96
[6]
PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME [J].
CASEY, LC ;
BALK, RA ;
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :771-778
[7]
Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction [J].
Chan, AW ;
Chew, DP ;
Bhatt, DL ;
Moliterno, DJ ;
Topol, EJ ;
Ellis, SG .
AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (02) :132-136
[8]
LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock - A prospective randomized study [J].
Cotter, G ;
Kaluski, E ;
Milo, O ;
Blatt, A ;
Salah, A ;
Hendler, A ;
Krakover, R ;
Golick, A ;
Vered, Z .
EUROPEAN HEART JOURNAL, 2003, 24 (14) :1287-1295
[9]
L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock [J].
Cotter, G ;
Kaluski, E ;
Blatt, A ;
Milovanov, O ;
Moshkovitz, Y ;
Zaidenstein, R ;
Salah, A ;
Alon, D ;
Michovitz, Y ;
Metzger, M ;
Vered, Z ;
Golik, A .
CIRCULATION, 2000, 101 (12) :1358-1361
[10]
Sites of interleukin-16 release in patients with acute coronary syndromes and in patients with congestive heart failure [J].
Deliargyris, EN ;
Raymond, RJ ;
Theoharides, TC ;
Boucher, WS ;
Tate, DA ;
Dehmer, GJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (09) :913-918